70380-49-3

Usage

Chemical Properties

Yellow Solid

Uses

Intermediate in the preparation of Anagrelide.

InChI:InChI=1/C7H6Cl2N2O2/c8-5-1-2-6(11(12)13)4(3-10)7(5)9/h1-2H,3,10H2

Synthetic route

phthalimide (136918-14-4) + 1,2-dichloro-3-chloromethyl-4-nitrobenzene (192124-88-2) → 2,3-dichloro-6-nitrobenzylamine (70380-49-3)

2,3-dichloro-6-nitrobenzylamine (70380-49-3) + ethyl bromoacetate (105-36-2) → ethyl N-(2,3-dichloro-6-nitrobenzyl)glycine hydrochloride

Conditions	Yield
With triethylamine In 1,4-dioxane; ethanol

2,3-dichloro-6-nitrobenzylamine (70380-49-3) + ethyl bromoacetate (105-36-2) → N-(2,3-dichloro-6-nitrobenzyl)glycine ethyl ester hydrochloride (70380-50-6)

Conditions	Yield
Stage #1: 2,3-dichloro-6-nitrobenzylamine; ethyl bromoacetate With triethylamine In 1,4-dioxane at 90 - 100℃; for 4h; Stage #2: With hydrogenchloride In water; ethyl acetate; isopropyl alcohol at 20 - 30℃;

Upstream product

• 136918-14-4 phthalimide 
• 192124-88-2 1,2-dichloro-3-chloromethyl-4-nitrobenzene 

Downstream Products

• 70380-50-6 N-(2,3-dichloro-6-nitrobenzyl)glycine ethyl ester hydrochloride 

Relevant academic research and scientific papers

2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof

The compound 2-amino-5,6-dichloro-3,4-dihydroquinazoline has been found to have enhanced platelet count reducing properties. Also provided are methods for synthetically making the compound and a method of reducing the platelet count in a patient by administering to the patient a platelet reducing effective amount of the compound preferably together with a pharmaceutically acceptable carrier. A pharmaceutical composition is also provided which contains the above compound as the active ingredient together with pharmaceutically acceptable excipients.

Alkyl 5,6-dichloro-3,4-dihydro-2(1H)-iminoquinazoline-3-acetate hydrohalides

The known blood platelet antiaggregative agent 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one is prepared in high yield via an improved process involving a novel intermediate of the Formula STR1 in which R1 is (lower)alkyl and X is bromo, chloro or iodo. Two processes for the preparation of compounds of the Formula III are disclosed, one of which involves the novel intermediate STR2